Prostate Cancer - Results from #2020

Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. October 13, 2023

Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men. October 13, 2023

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. October 13, 2023

Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. October 13, 2023

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients. October 12, 2023

Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer. October 12, 2023

Global Variation in Magnetic Resonance Imaging Quality of the Prostate. October 12, 2023

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. October 12, 2023

Long-term quality-of-life outcomes following prostate radiotherapy with or without high-dose-rate brachytherapy boost: post-hoc analysis of TROG 03.04 RADAR. October 12, 2023

Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study. October 12, 2023

A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. October 12, 2023

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer October 11, 2023

Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol. October 11, 2023

A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer. October 11, 2023

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. October 11, 2023

A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. October 11, 2023

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial. October 11, 2023

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. October 11, 2023

Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study October 10, 2023

First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial October 10, 2023

Page 102 of 1439